Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase I Study of Milatuzumab for Graft Versus Host Disease
† Study has passed its completion date and status has not been verified in more than two years.